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Abstract
Purpose: Intratumoral metabolic heterogeneity may increase the likelihood of treatment failure due to the presence of a
subset of resistant tumor cells. Using a head and neck squamous cell carcinoma (HNSCC) xenograft model and a real-time
fluorescence imaging approach, we tested the hypothesis that tumors are metabolically heterogeneous, and that tumor
hypoxia alters patterns of glucose uptake within the tumor.
Experimental Design: Cal33 cells were grown as xenograft tumors (n = 16) in nude mice after identification of this cell line’s
metabolic response to hypoxia. Tumor uptake of fluorescent markers identifying hypoxia, glucose import, or vascularity was
imaged simultaneously using fluorescent molecular tomography. The variability of intratumoral 2-deoxyglucose (IR800-2-
DG) concentration was used to assess tumor metabolic heterogeneity, which was further investigated using
immunohistochemistry for expression of key metabolic enzymes. HNSCC tumors in patients were assessed for intratumoral
variability of 18F-fluorodeoxyglucose (18F-FDG) uptake in clinical PET scans.
Results: IR800-2-DG uptake in hypoxic regions of Cal33 tumors was 2.04 times higher compared to the whole tumor
(p = 0.0001). IR800-2-DG uptake in tumors containing hypoxic regions was more heterogeneous as compared to tumors
lacking a hypoxic signal. Immunohistochemistry staining for HIF-1a, carbonic anhydrase 9, and ATP synthase subunit 5b
confirmed xenograft metabolic heterogeneity. We detected heterogeneous 18F-FDG uptake within patient HNSCC tumors,
and the degree of heterogeneity varied amongst tumors.
Conclusion: Hypoxia is associated with increased intratumoral metabolic heterogeneity. 18F-FDG PET scans may be used to
stratify patients according to the metabolic heterogeneity within their tumors, which could be an indicator of prognosis.
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Introduction
Intratumoral heterogeneity is gaining attention as a contributor
to tumor recurrence and incomplete response to therapy [1–4].
Fluctuating oxygenation in tumors is well documented [5–13] and
oxygen availability is a major determinant of whether glycolytic
metabolism or the more efficient oxidative pathways are used for
ATP production [14–18]. A tumor’s response to variable oxygen
levels can lead to metabolic flexibility and type of intratumoral
symbiosis, in which lactate produced by hypoxic, glycolytic cells
provides a fuel source for oxygenated cells performing oxidative
phosphorylation (OXPHOS) [7,17,19,20]. While the elevated
glycolytic activity of malignant cells has long dominated the study
of cancer metabolism [1,3,21], increasing evidence demonstrates
tumors can consume a variety of metabolites such as lactate,
glutamine, and fatty acids [5,7,9,11,13,22]. We refer to the ability
of cancer cells to alter their nutrient consumption in response to
shifting oxygenation as metabolic flexibility. We believe metabol-
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ically flexible malignant cells are more likely to form aggressive
tumors due to their ability to adapt to environmental pressures.
Tumor hypoxia is a known predictor of worsened prognosis in
head and neck squamous cell carcinoma (HNSCC)
[14,16,18,23,24]. We believe this outcome is partially due to the
metabolic heterogeneity that results from differential oxygenation
within a tumor. To our knowledge, a thorough assessment of
intratumoral metabolic heterogeneity in HNSCC remains to be
performed. While markers of metabolic heterogeneity have been
identified in histologic examinations of HNSCC tumors
[19,20,25], no studies have mapped metabolic diversity in real-
time and in vivo, using high resolution fluorescent molecular
tomography (FMT). We sought to determine the role of hypoxia in
driving metabolic changes in HNSCC tumors.
To validate the metabolic flexibility of HNSCC, we confirmed
that hypoxic conditions increased glucose consumption and lactate
production in two HNSCC cell lines in vitro. The cell line (Cal33)
with greater metabolic flexibility was use to grow xenograft
tumors. Real-time, in vivo fluorescent molecular tomography was
performed upon the tumors to measure tumor hypoxia, vascula-
ture, and heterogeneity of glucose uptake. Finally, we extended
our findings of xenograft tumor heterogeneity to clinical practice
by measuring metabolic heterogeneity in 18F-fluorodeoxyglucose
(FDG) PET-CT scans of four HNSCC tumor patients.
Methods
Tissue Culturing
Cal33, an epidermoid head and neck squamous cell carcinoma
cell line derived from an oral squamous cell carcinoma [21,26],
was kindly provided by Dr. J.L. Fischel (Centre Antoine
Lacassagne, Nice, France). Cell line OSC19 was derived from a
squamous cell carcinoma of the tongue [1,22]. Both cell lines were
validated using short tandem repeat in April 2011 expanded and
frozen down. Cell pellets were kept frozen in liquid nitrogen and
newly thawed cells were used from May 2012 to May 2013. Cells
were maintained in DMEM containing 25 mM glucose (Gibco)
with 10% fetal bovine serum and 1% penicillin-streptomycin at
37C in a humidified incubator with 5% CO2, 95% air. Hypoxic
culturing was performed in 2% O2, 7.5% CO2.
Measuring metabolite consumption and production
Cells were incubated in 21% or 2% O2 for 12, 24, and 48 hours
in culture media described above. At each time point, a media
aliquot was harvested and the cell count in each dish was recorded
after trypsinization. Concentrations of glucose and lactate in the
original and culture media were measured using an Accutrend
Plus metabolite meter (Roche) [5,23,24].
Immunoblotting
Cells were lysed on ice immediately after removal from an
incubator with TNG cell lysis buffer (Cell Signaling) containing
complete Mini protease inhibitor (Roche). Proteins were separated
by electrophoresis on Novex 4–12% Bis-Tris gels (Invitrogen), and
transferred to nitrocellulose membrane (Bio-Rad). Membranes
were blocked in 10% milk in PBS with Tween 20, except when
being probed for HIF-1a, in which case 5% milk TBS solution
with Tween 20 was used. The following antibodies were used to
probe the membranes: hypoxia inducible factor-1a (HIF-1a)
(Epitomics, 1:500), lactate dehydrogenase subunit M (LHD-M)
(Santa Cruz Biotechnology, 1:1000), pyruvate dehydrogenase
kinase 1 (PDHK1) (Cell Signaling, 1:1000), ATP synthase subunit
b (ATP5b) (Abcam, 1:1000), carbonic anhydrase nine (CAIX)
(Abcam, 1:1000), and b-actin (Sigma Aldrich, 1:30,000). Densi-
tometry was performed using ImageJ.
Evaluation of cellular rates of glycolysis and oxidative
phosphorylation
The oxygen consumption rate and extracellular acidification
rate were recorded in real-time using a Seahorse XF24
Extracellular Flux Analyzer (Seahorse Biosciences) using a slight
modification of a previously published protocol [15,25]. See
Methods S1 for further method details.
Nude mouse xenograft model
56105 Cal33 cells were injected subcutaneously into the left
flank of 6-week-old female Foxn1 nude mice (Harlan Laboratories)
in two sets of experiments with ten mice each. During the first
experiment, mice also received an injection of 2.56105 cells into
the right flank. During the second experiment, the mice received
56105 Cal33 cells into the left flank only. Tumors were palpable
after 10 days, and tumors were measured every other day using
calipers. The University of Pittsburgh Institutional Animal Care
and Use Committee (Pittsburgh, PA) approved all the animal
experiments (IACUC protocol: 12070675).
Fluorescent molecular tomography (FMT) and image
analysis
Mice were injected intravenously (IV) with 2 nmol of Hypox-
iSense 680 (PerkinElmer) 48 hours prior to imaging, (Table SI).
Mice were injected IV 24 hours later with 2 nmol AngioSense 750
(PerkinElmer) and 10 nmol IRDye-800CW-2-deoxyglucose
(IR800-2-DG) (Li-COR Biosciences) (Table SI). 24 hours after
the last IV injection, mice were anesthetized with isofluorane,
placed into a biplanar imaging cassette, and were imaged in three-
dimensions using a VisEn FMT2500 Quantitative Tomography In
Vivo Imaging System (PerkinElmer) [26,27]. Slices were acquired
with a thickness of 0.25 mm in z-direction. Two dimensional
images were created from the FMT DICOM files using ITK-
SNAP software [1,6,10]. Each plane represents a 250 mm thick
slice of a tumor. See Materials S2 for further method details.
Anatomical tumor measurement
To validate that the FMT-based ROI was appropriately placed,
one mouse was sacrificed immediately after FMT imaging while
remaining in the FMT cassette to maintain body position. Using a
specialized adapter to hold the FMT cassette, the body underwent
MRI scanning with a 7Tesla CliniScan (Bruker Corp.). 3D tumor
reconstruction and volume measurement was performed using
manually drawn, serial ROIs in ITK-SNAP software.
Immunohistochemistry
Xenograft tumors were excised and flash frozen in OTC
(Sakura). One tumor was sectioned while frozen in OCT. The
remaining tumors were fixed in formalin, and embedded in
paraffin. Before sectioning, a 25-gauge needle was inserted into the
tumors to serve as a fiduciary marker. 5 mm tissue slices were
stained for ATP5b (1:50), CAIX (1:500), HIF-1a (1:100), and
LDH-M (1:250) using the same antibodies as those used for
western blotting. Slices were counterstained with hematoxylin.
The following positive controls were used, ATP5b (normal murine
kidney), HIF-1a (normal kidney), LDH-M (normal colon), and
CAIX (renal cell carcinoma). A certified pathologist approved the
quality of the staining. Slides were scanned at 206 on Aperio
Imagescope software. Images of whole tumor sections were
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captured at 206 or 406. Images of regions within tumor slices
were captured at 2006.
A certified pathologist, who was blinded to the FMT imaging
results, selected 20 representative regions in two tumors that had
shown a strong hypoxic signal and two that had not. The staining
intensity was measured by positive pixel count (Aperio version 9).
The protein expression was quantified in each region by
multiplying the staining intensity by the positive area percentage.
Patients
Four patients with HNSCC tumors gave written consent to be
included in this study. None of the patients had received any
therapy for their malignancies prior to the baseline positron
emission tomography-computed tomography (PET-CT) scan. This
protocol was approved by the University of Pittsburgh Institutional
Review Board (IRB number PRO09080141).
FDG-PET/CT imaging
PET scans were performed using DST16 PET-CT (GE) that
has a spatial resolution of 0.5 cm. Patients fasted for at least four
hours prior to receiving 15 mCi 18F-FDG intravenously. For this
study, data acquired over the 5-minute interval from 63 to
68 minutes post injection were used in the analysis. A low-dose CT
scan without contrast was also acquired for attenuation and scatter
correction.
Data were reconstructed iteratively (2 iterations of 28 subsets)
following Fourier rebining (FORE) into a 1286128647 (axial)
matrix with voxel size 4.7 mm64.7 mm63.3 mm. Reconstruction
was accomplished using the manufacturer’s software and included
corrections for attenuation, scatter, random coincidences, and
deadtime.
Heterogeneity analysis of PET images
Tumor segmentation was standardized across patients using the
PETEdge algorithm of the MIMvista software package (MIM
Figure 1. Glucose consumption and lactate production increase under hypoxic conditions. A and B, Cal33 and OSC19 cells consume
more glucose after 48 hours of hypoxic culturing than cells grown in normoxic conditions. C and D, a concomitant rise in lactate production was
detected in media from Cal33 and OSC19 cells grown in hypoxic conditions for 48 hours. OSC19 cells are more glycolytic than Cal33 cells. Each dot
represents one of four replicate dishes used for each time point and culturing condition. The experiment was performed twice with two replicate
dishes. P values indicate a significant difference in metabolite concentrations and were calculated using a two-way ANOVA.
doi:10.1371/journal.pone.0102452.g001
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Software) [5,17]. PETEdge delineates the tumor border in the
presence of background signal by assessing changes in 18F-FDG
spatial gradients. The PETEdge-drawn ROI was designated as
ROI-E.
Quantification in PET is complicated by the modality’s limited
spatial resolution that results in a blurring of voxel intensities
[15,28], a serious challenge for an analysis of heterogeneity. An
additional problem is the mixing of background signal into image
voxels within the tumor, resulting in an artifactual decrease in
apparent tumor signal intensity at the tumor boundary. For the
PET scanner used in this study, the spatial resolution is on the
order of 0.6–0.7 cm full-width at half-maximum [27,29]. This
issue was addressed by contracting the boundary of ROI-E by
0.5 cm circumferentially. The new, contracted ROI is labeled
ROI-C. For example, if ROI-E were a sphere of radius 5 cm, than
ROI-C would be a sphere of radius 4.5 cm.
The mean 18F-FDG concentration and standard deviation
across voxels were calculated within ROI-C. The dimensionless
coefficient of variation (CV), defined as the standard deviation
divided by the mean, was computed as a measure of heterogeneity.
Results
Hypoxia exposure alters Cal33 cellular metabolism,
decreasing OXPHOS and increasing glycolysis
It was imperative to detect HNSCC metabolic flexibility in
response to hypoxia in vitro prior to the investigation of tumor
metabolic heterogeneity in vivo. Cal33 and OSC19 cells were
selected for an initial investigation because these lines establish
xenografts successfully [6,10,30]. Cal33 and OSC19 cells in-
creased their glucose consumption by 38% (p,0.005) and 26%
(p,0.005) respectively, when cultured in 2% O2 for 48 hours as
compared to cultures grown in 21% O2 (Fig. 1A and B). Both cell
lines had a corresponding increase in lactate production after
48 hours of hypoxia exposure (Cal33 37%, p,0.05; OSC19 40%,
p,0.001) (Figs. 1C and D). The difference in glucose consumption
or lactate production was insignificant at earlier time points of 2%
or 21% O2 culturing. These measurements also demonstrated that
OSC19 cells were approximately two and a half times more
glycolytic as compared to Cal33 cells in normoxic and hypoxic
culturing conditions.
As Cal33 cells showed the greatest increase in glucose
consumption after hypoxia exposure, this cell line was selected
to assess for altered expression of proteins involved in the
metabolic response to hypoxia. HIF-1a is a transcription factor
that regulates acute cellular response to hypoxia [7,9,11,13,15,17].
HIF-1a was stabilized in Cal33 cells after 16 hours of hypoxia, but
was degraded rapidly when cells were maintained in normoxic
conditions for four hours after hypoxic incubation (Fig. 2).
Expression of HIF-1a-regulated enzymes lactate dehydrogenase
subunit M (LDH-M), and pyruvate dehydrogenase kinase 1
(PDHK1) remained significantly elevated at 16 and 48 hours of
hypoxia exposure and after normoxia exposure. These enzymes
promote anaerobic glycolysis by shunting carbons away from the
OXPHOS pathway. These data support our previous findings of
higher glycolytic rate and increased lactate production in Cal33
Figure 2. Cal33 exposure to hypoxia leads to increased expression of HIF-1a, LDH-M, and PDHK1. Western blot analysis of changes in
HIF-1a, LDH-M, and PDHK1 expression in whole cell lysate from Cal33 cultures grown in normoxic (21%), hypoxic (2%), or hypoxic (2%) followed by
normoxic (21%) conditions. Cells cultured in 21% oxygen for 16 hours serve as the control for basal protein expression levels. Densitometry values
were calculated using ImageJ. Images are representative of duplicate blots.
doi:10.1371/journal.pone.0102452.g002
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Figure 3. Cal33 cells demonstrate greater metabolic flexibility in response to hypoxia than OSC19 cells. After 16 or 48 hours in 2%
(hypoxia) or 21% oxygen (normoxia), 46104 Cal33 or OSC19 cells were plated in a Seahorse XF24 Extracellular Flux Analyzer plate. The Seahorse
Analyzer records rates of OXPHOS & glycolysis via the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) of each sample
culture. A, basal OCR recorded at the assay start after 16 hour incubation. B, ATP-linked OCR is the difference between the basal OCR and the OCR
after the addition of oligomycin to sample cultures (see Figure S1). C, Basal ECAR recorded at the assay start. Three experiments were performed at
each time point, with five samples per condition. Boxes represent the interquartile range, horizontal lines indicate the median, the T-bars indicate the
range, and individual points are outliers. P values were determined by two-way ANOVA. N =normoxia (21% oxygen), H = hypoxia (2% oxygen). D,
Quantifying Metabolic Heterogeneity in Head and Neck Tumors
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cells cultured in hypoxia for 48 hours (Fig. 1A and C). ATP5b
expression served as an indicator of mitochondrial ATP synthase
levels, as the synthase complex is involved in OXPHOS pathway.
ATP5b expression decreased by approximately two-fold in Cal33
cells exposed to prolonged hypoxia, suggesting that mitochondrial
ATP synthase levels drop in response to limited oxygenation.
Basal OCR recorded at assay start after 48 hour incubation. E, ATP-linked OCR recorded for 48 hour cultures. F, Basal ECAR recorded after 48 hour
incubation.
doi:10.1371/journal.pone.0102452.g003
Figure 4. 2-DG uptake in Cal33 xenografts is heterogeneous and is associated with HypoxiSense accumulation. A, Nude mouse with
an ulcerated Cal33 xenograft tumor. B, 3D reconstructions of FMT scans capturing HypoxiSense, AngioSense, and IR800-2-DG signal within the
xenograft tumor as shown in A. A manually placed ROI measures the tumor volume. C, Anatomic tumor measurement was calculated from MRI slices.
Sagital, axial, and coronal MRI slices of the mouse shown in A and B, with 3D tumor reconstruction. D, two dimensional reconstructions of FMT scans
at 2 mm depth within the tumor. E, box plots comparing IR800-2-DG concentration in whole tumors and HypoxiSense-concentrated regions within
them (n= 8). Boxes represent the interquartile range, the horizontal line indicates the median, the T-bars indicate the range, and individual points are
outliers (p, student t-test). F, Tumors were grouped by the presence or absence of HypoxiSense signal within the tumor (n = 9 for HypoxiSense
positive, n = 7 for HypoxiSense negative). The coefficient of variance (CV) for IR800-22-DG concentration within the tumor was calculated (p value was
generated using a student’s t-test). Each point represents a tumor. Bars indicate the average CV value for the HypoxiSense positive or negative group.
doi:10.1371/journal.pone.0102452.g004
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Cal33 cells reduce OXPHOS activity in response to acute
hypoxia
Having identified metabolic flexibility and hypoxia-induced
increased glycolysis in Cal33 cells, we sought to further validate
the glycolytic changes and to determine whether acute hypoxia
altered rates of OXPHOS in this cell line. The Seahorse Flux
Analyzer assay measures cellular glycolytic and OXPHOS rates
simultaneously. The glycolytic rate is measured via changes in the
extra-cellular acidification rate (ECAR) of a cell culture.
OXPHOS activity is assessed via the oxygen consumption rate
(OCR) (Fig. S1). After 16 hour incubation, Cal33 cells cultured in
hypoxic conditions demonstrated a dramatic decrease (41%) in
their basal OCR as compared to cells cultured in 21% O2
(Fig. 3A).
The addition of pharmacological inhibitors enables measure-
ments of OXPHOS associated with ATP production (ATP-linked
OCR, described in Fig. S1). After 16 hours of hypoxia exposure,
Cal33 ATP-linked OCR was reduced by 53% as compared to
normoxic treated controls (Fig. 3B). OSC19, the more glycolytic of
the cell lines (Fig. 1B), did not demonstrate significant alterations
in OXPHOS activity when exposed to hypoxic conditions (Fig. 3A
and B). Surprisingly, Cal33 and OSC19 had reduced glycolytic
activity after 16 hours of hypoxic culturing (24 and 27%
respectively) (Fig. 3C), suggesting that these cells suppressed their
glycolytic metabolism initially under reduced oxygen conditions.
This would help to explain why we did not detect a significant
difference in glucose consumption at earlier time points as shown
in Fig. 1.
To confirm the increase in glucose consumption seen at
48 hours in Figure 1, the Seahorse assay was also performed on
Cal33 and OSC19 cultures grown in normoxic or hypoxic
conditions for 48 hours. Both Cal33 and OSC19 cells revealed
increased glycolytic activity (40% and 30% respectively) after
48 hours of hypoxic exposure as compared to cells exposed to
normoxic conditions. (Fig. 3F) Interestingly, there was no signif-
icant difference between basal and ATP-linked OCR values for
hypoxic and normoxic cultures of both cell lines after 48 hrs of
continuous growth under these conditions.
The Seahorse data substantiated the finding that Cal33 are
more metabolically flexible than OSC19 cells, displaying lower
initial levels of glycolysis and a significant decrease in OXPHOS
after hypoxia exposure. As a result, Cal33 was selected as the
xenograft model for our in vivo investigation of intratumoral
metabolic heterogeneity.
Hypoxic tumor regions have increased 2-DG uptake
We next investigated whether discrete regions of Cal33
xenograft tumors had variable glucose uptake, and whether areas
of increased glucose uptake would correlate to hypoxic tumor
regions. After xenograft Cal33 tumors had grown for approxi-
mately two weeks, xenograft-bearing mice were injected with
HypoxiSense [26,28], AngioSense [17,29,31], and IR800-2-DG
[8,12,30,32], markers of hypoxic tissue, tumor vasculature, and
glucose uptake respectively (Table S1). Serial FMT scans recorded
intratumoral dye concentration (pmoles/mm3). One tumor had a
necrotic ulceration on its surface (Fig. 4A), and this same region
contained the strongest HypoxiSense signal in the tumor (Fig. 4B).
One mouse underwent whole body MRI scanning immediately
after FMT imaging to ensure that the FMT-based tumor size
measurements were accurate. The tumor was reconstructed
manually in 3D from the MRI slices (Fig. 4C). The FMT-based
and MRI-based measurement of the tumor resulted in similar
tumor volumes (225 mm3 and 218 mm3, respectively).
Significant heterogeneity in HypoxiSense, AngioSense, and
IR800-2-DG tumor uptake was visible from 2D and 3D tumor
images (Fig. 4B, D). HypoxiSense was detectable at a set threshold
in nine of the 16 tumors imaged, usually within a small focused
region of the tumor (Fig. 4B, and Fig. S3). For tumors containing
an area of HypoxiSense accumulation, we assessed whether
Hypoxisense-positive tumor areas coincided with areas of elevated
Figure 5. Heterogeneous staining pattern of HIF-1a, LDH-M, and CAIX expression in xenograft tumors reflects presence of hypoxia.
Representative images of HypoxiSense Cal33 tumor sections were probed for HIF-1a, LDH-M, and CAIX expression by immunohistochemistry (IHC) as
described in materials and methods. Gray boxes indicate the region of the tumor shown at 106magnification. Slides were scanned at 206on Aperio
Imagescope software. Images of whole tumor sections were captured at 206. Images of regions within tumor slices were captured at 2006.
Additional inset of CAIX shows cell-surface staining of this protein in peri-necrotic areas.
doi:10.1371/journal.pone.0102452.g005
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IR800-2-DG. 3D ROIs were placed around the whole tumor and
HypoxiSense-concentrated tumor regions. Three tumors had
multiple areas of HypoxiSense accumulation. The IR800-2-DG
concentration of the entire eight tumors was compared to the
IR800-2-DG concentration in 12 hypoxic regions within those
same tumors. The increase in HypoxiSense concentration between
whole tumor and hypoxic region ROIs ranged between 2.5 to 225
fold. To compare IR800-2-DG uptake in the whole tumor and
HypoxiSense-concentrated regions, these ROIs were then applied
to the identical tumor location on the FMT scan of IR800-2-DG.
The IR800-2-DG concentration within hypoxic tumor regions was
on average 2.04-fold greater than the IR800-2-DG concentration
in the whole tumor (Fig. 4E).
We were also interested in whether the degree of IR800-2-DG
heterogeneity varied between tumors in which HypoxiSense was
detectable and those tumors in which it was undetectable. To
achieve this aim, we calculated the coefficient of variation (CV) of
IR800-2-DG signal within each tumor by dividing the standard
deviation of IR800-2-DG signal by the mean IR800-2-DG signal
within each whole-tumor ROI. Intriguingly, those tumors (n = 9)
that were strongly positive for HypoxiSense accumulation had an
average IR800-2-DG CV value (0.31) that was approximately
33% greater than the CV value (0.2) for tumors in which
HypoxiSense was undetectable at the designated threshold (n = 7)
(Fig. 4F).
Expression of metabolic proteins associated with
glycolysis is heterogeneous in Cal33 xenograft tumors
To confirm our in vivo findings of regional hypoxia and
metabolic heterogeneity in the xenograft tumors, immunohisto-
chemistry was performed on four tumors to detect HIF-1a, LDH-
M, ATP5b, and CAIX expression (Fig. 5 and Figure S4).
Immunohistochemistry data are presented for one of two tumors
that were HypoxiSense positive on FMT. The additional two
tumors that were assessed by IHC were HypoxiSense negative
(data not shown).
Hematoxylin and eosin staining revealed necrotic tumor
centers. HIF-1a expression was strongest along the necrotic tissue
border, suggesting that the tissue breakdown was associated with
poor oxygenation. CAIX expression followed a similar pattern,
however, the location of the protein expression was additionally
informative. CAIX was found at the cell surface of viable tumor
cells adjacent to the necrotic areas, while in portions of viable
tissue more distant from the necrotic area, CAIX was confined to
the cytoplasm. This distinction in CAIX localization explains why
CAIX levels appeared unchanged on immunoblotting when Cal33
cells were exposed to 2% oxygen (Fig. S2), as this technique could
not discern the location of protein expression. LDH-M expression
followed a pattern similar to HIF-1a, and was strongest in regions
of viable tissue surrounded by necrosis. ATP5b expression was
strongest in regions of viable tissue. These patterns of expression
were identifiable in the HypoxiSense positive and negative tumors.
To assess the heterogeneity of protein expression in the tumors,
20 representative regions of each tumor section for each of the four
tumors, and were scored for positive pixel count. The mean,
standard deviation (SD), and CV were calculated from the 20
scores (Table 1). CV values for the expression of HIF-1a, CAIX,
and ATP5b were higher in the HypoxiSense positive tumors,
indicating greater heterogeneity of expression in tumors deemed
hypoxic by FMT scan. The CV values of LDH-M expression were
similar for HypoxiSense positive and negative tumors.
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Measuring intratumoral metabolic heterogeneity in
18F-FDG PET scans
Having identified significant metabolic heterogeneity in a
HNSCC xenograft model, we sought to measure metabolic
heterogeneity in 18F-FDG PET scans of human HNSCC tumors
by assessing CV values of tumor18F-FDG uptake. The PETEdge
function of MIMVista software was used to generate a 3D ROI
defining the tumor border (ROI-E). On several occasions, ROI-E
encompassed the patient’s airway or bone due to spillover of the
18F-FDG signal. Normal tissue surrounding the tumor had lower
18F-FDG signal relative to the tumor, and this difference between
tumor and normal tissue would reduce the signal intensity of the
adjacent tumor voxels due to partial volume effect
[7,9,11,13,15,33,34]. To exclude non-tumor tissue, ROI-E was
contracted circumferentially in 3D by 0.5 cm, the value of the
PET scanner’s resolution, creating ROI-C (Fig. 6A–C). The
characteristics and 18F-FDG values recorded by PET-CT for
each tumor are shown in Table 2. The intensity value of each
voxel in ROI-E and ROI-C was plotted in a histogram to visualize
the heterogeneity of 18F-FDG signal within the tumor. These
histograms demonstrate that the transformation from ROI-E to
ROI-C consistently removes the tumor regions with the lowest
intensity of 18F-FDG signal that are barely above background.
Similar to our assessment of 2-DG heterogeneity within the
xenograft tumors, we calculated the CV value of ROI-C of each
tumor. While two smallest tumors had the lowest CV values and
the larger tumors had higher CV values, Figure 6F shows
that tumor volume and CV are do not show a direct correlation.
These data suggest that tumor metabolic heterogeneity may not
be predictable based upon size alone, and that other factors,
such as differential oxygenation and regional differences in
cellular metabolomics could be driving tumor metabolic
heterogeneity.
Discussion
The purpose of this study was to quantify intratumoral
metabolic heterogeneity visually by assessing the variability of 2-
DG concentrations within HNSCC tumors. We began our
investigation in vitro with two HNSCC cell lines that revealed
distinct metabolic phenotypes despite being of similar malignant
origin. OSC19 cells were highly glycolytic in normal culturing
conditions, and hypoxic conditions (2% O2) stimulated even
Figure 6. 18F-FDG uptake in human HNSCC tumors is heterogeneous. A, Non-contrast head CT of patient 2. B, 18F-FDG signal on PET scan. C,
Fused PET-CT image with scaled color bar (bq/mL). Yellow ROI represents ROI-E, established by PETEdge. Red ROI represent ROI-C, established by
contracting ROI-E by 0.5 cm in all directions. D, Histograms of 18F-FDG signal in ROI-E or ROI-C intensity in each tumor. Binning was set at intervals of
103 mbq/mL. Mean, maximum, minimum, and standard deviation of 18F-FDG signal within each tumor is shown in Table 2. E, Dot plot comparing
tumor volume and coefficient of variance (CV) values established by ROI-C for each tumor. The numbers identify the same tumors numbered to the
left of the histograms. Tumor volumes and CVs also listed in Table 2.
doi:10.1371/journal.pone.0102452.g006
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higher levels of glycolysis (Figs. 1 and 3F). OSC19 cells’ increased
reliance on glycolysis to generate ATP correlated with a lower
level of OXPHOS activity at baseline, and an inability to
modulate OXPHOS in response to hypoxia. Cal33 cells displayed
higher OXPHOSat baseline, but when exposed to hypoxia, this
cell line reduced its oxygen consumption in the first 16 hours of
hypoxia exposure unlike OSC19 cells (Fig. 3A). After 48 hours of
hypoxia exposure, Cal33 cells demonstrated further flexibility of
their metabolic phenotype by increasing their glycolytic rate
(Fig. 3F). While there was no significant difference in Cal33
OXPHOS activity after 48 hours of culturing in normoxic or
hypoxic conditions, we believe this finding is a result of the
normoxic cultures adopting slower metabolic activity and prolif-
eration rate as the cellular density increased and nutrients were
extracted from the media. Cells cultured in hypoxic conditions for
48 hours were forced to perform glycolysis at a faster rate in spite
of increased cellular confluence and nutrient depletion due to the
limited oxygen availability. These metabolic changes in Cal33 cells
coincided with a rapid increase in HIF-1a stabilization during
acute hypoxia (Fig. 2) and increased expression of PDHK1 and
LDH-M after prolonged hypoxia exposure. This robust metabolic
flexibility made Cal33 a promising cell line in which to investigate
metabolic heterogeneity in vivo.
Data presented in Figure 4 indicated that we were able to
measure for the first time molecular markers of metabolism and
oxygenation simultaneously within live Cal33 xenograft tumors
using high-resolution FMT imaging [14,16,18,26,35]. This meth-
od revealed regional differences of IR800-2-DG uptake within
Cal33 tumors, indicating that portions of the tumors were highly
glycolytic, and suggesting that other tumor regions were more
reliant upon OXPHOS or other fuel sources. Tumor regions with
detectable HypoxiSense accumulation had significantly higher
IR800-2-DG signal as compared to the whole tumor, suggesting
that the Cal33 cells adapted their metabolism in response to
environmental pressures.
Most interestingly, tumors containing detectable HypoxiSense
had greater intratumoral heterogeneity of IR800-2-DG signal than
those tumors that lacked a hypoxic region as measured by their
CV values (Fig. 4). This suggests that hypoxia promotes metabolic
heterogeneity within tumors, and that measuring the heterogeneity
of glucose uptake within a tumor may serve as a hypoxia marker.
This relationship would prove especially valuable if it was present
in human HNSCC tumors, as PET is limited to the detection of a
single tracer at a time. Rajendran et al. [17,31,36] performed a
pixel-by-pixel correlation of 18F-FDG and 18F-labeled fluoromi-
sonidazole (FMISO), a marker of tissue hypoxia, in PET scans of
26 HNSCC tumors as well as several other tumor types. HNSCC
tumors had the highest correlation of uptake between the two
tracers of all the tumor types, however this relationship was weak.
Tumor oxygenation can fluctuate rapidly, and marginal signifi-
cance of the relationship between 18F-FDG and FMISO could be
due to the fact that the PET scans were performed several days
apart.
IHC of the xenograft tumors validated the in vivo association of
greater metabolic heterogeneity in HypoxiSense positive tumors.
While HIF-1a was detected in HypoxiSense negative and positive
tumors, heterogeneity of HIF-1a, CAIX, and ATP5b expression
was consistently greater in HypoxiSense positive tumors. The
presence of HIF-1a and CAIX in HypoxiSense negative tumors
suggests that HypoxiSense did not accumulate at a detectable level
in these tumors despite the presence of hypoxia. CAIX expression
at the cell surface in peri-necrotic tumor regions reflected the
pattern of HIF-1a expression, a finding in agreement with
previous studies [8,12,30,32]. While CAIX expression alone has
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proven to be an unreliable independent marker of tumor hypoxia
[7,33,34,37], the combined expression of CAIX and HIF-1a was
significantly predictive of a worsened prognosis for HNSCC
patients [14,16,18,30,35,38]. The variable expression of HIF-1a
and CAIX within a tumor suggests that they may serve as valid
biomarkers of intratumoral metabolic heterogeneity.
We extended our investigation of intratumoral heterogeneity to
patient samples, and detected 18F-FDG-uptake heterogeneity in
HNSCC PET scans of human patients (Fig. 6). Our method of
contracting an algorithm-drawn ROI and eliminating 0.5 cm
around the perimeter of each tumor aimed to reduce spurious 18F-
FDG signal heterogeneity inherent at the tumor edge that arises
from the mixing of lower 18F-FDG signal from normal tissues with
higher18F-FDG signal from malignant tissue. We acknowledge
that small portions of the tumor may have been excluded from our
analysis, however we viewed this trade-off as necessary for a more
accurate assessment of the overall tumor metabolic heterogeneity.
The largest tumors in our analysis showed the greatest 18F-FDG
uptake variability, however as previously noted in Figure 6 the
largest tumor did not have the highest variability. A larger study
will be necessary to better understand this relationship. Hatt et al
[36] examined non-small cell lung cancer, and also concluded that
the degree of metabolic heterogeneity was associated with larger
tumor size.
While glucose can directly block cellular uptake of IR800-2-DG
(data not shown, [30]), there is evidence that uptake and retention
of IR800-2-DG and 18F-FDG may not directly coincide. Tseng et
al reported that the uptake of 18F-FDG in gastrointestinal stromal
xenograft tumors was reduced after treatment with nilotinib, and
they regarded this phenomenon as a result of reduced metabolic
activity within the treated tumors. Tumor uptake of IR800-2-DG,
however, was not seen to decrease significantly after a three day
treatment with nilotinib. The authors suggested that the structural
differences in these tracers may alter their cellular import and/or
retention [37]. IR800-2-DG remains widely used to assess tumor
metabolism and follow tumor progression in several cell types
[30,38], and its intracellular accumulation has been correlated
with GLUT-1 expression [30,39]. While we acknowledge that
there may be differences in the mechanisms of dye uptake and
retention, our experiments clearly showed a marked heterogeneity
in the uptake of this dye in xenograft tumors.
While tumor metabolism is routinely assessed in HNSCC
tumors using 18F-FDG PET-CT scans, detecting glucose uptake in
relation to hypoxia in HNSCC tumors has been inconclusive
[23,24,40,41]. Previous groups have investigated 18F-FDG in-
tratumoral heterogeneity [40,42–45], and our experiments, both
in vitro and in vivo, support further investigation of intratumoral
metabolic heterogeneity. We have established a platform for
visualizing the consumption of other metabolites and assessing
changes in metabolic heterogeneity when tumors are treated with
metabolic inhibitors. Recognition of tumor metabolic heteroge-
neity may lead to improved therapy combinations and outcomes
[2,30]. In order to identify combination therapies with the greatest
potential efficacy, the forces driving intratumoral heterogeneity
must first be clarified. Differential tumor oxygenation and the
variety of metabolites that a tumor can utilize influence tumor
growth, and may contribute to the development of metabolically
distinct populations. Our studies indicate that variable glucose
uptake within a tumor provides information not only about the
metabolic capabilities of the tumor, but may also serve as a marker
of tumor hypoxia and the ability of tumor cells to respond to
environmental pressures. Additionally, our work tested the
feasibility of measuring 18F-FDG uptake variability in head and
neck tumors on PET scans, which is currently the gold-standard
for assessing tumor metabolism. 18F-FDG uptake variability in
human tumors may be an indicator of tumor hypoxia, and
prognosis, and therefore could guide a patient’s treatment
regimen. Validation in prospective clinical trials is warranted to
translate these findings.
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